SLC2A1 and non-small cell lung carcinoma: WZB117, a GLUT1 inhibitor has been demonstrated to reduce Akt phosphorylation in NSCLC cells (Liu et al., 2012) or have no significant effect on p-Akt in MCF-7 or MDA-MB-231 cells (Li et al., 2019).